Can I Take Vitamin B6 with Retatrutide?

What Is Retatrutide and Why Does It Matter for Supplement Safety?

Retatrutide (LY3437943, Eli Lilly) is an investigational once-weekly subcutaneous peptide that simultaneously activates glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This triple agonism produces greater weight loss than dual GIP/GLP-1 agents in early trials.

Phase 2 Results at a Glance

The key Phase 2 dose-finding trial (NCT04881760, N=338) published in the New England Journal of Medicine in 2023 showed mean body-weight reductions of 17.5% at 24 weeks with the 12 mg dose, compared with 1.6% for placebo over the same period [1]. At 48 weeks, the 12 mg arm reached a 24.2% mean weight loss. These numbers exceed what semaglutide 2.4 mg achieved in STEP-1 (14.9% at 68 weeks, N=1,961) [2]. That weight-loss magnitude changes how clinicians think about every co-intervention, including supplements.

How Retatrutide Is Metabolized

Retatrutide is a large synthetic peptide. It is broken down by standard proteolytic pathways, not by cytochrome P450 enzymes (CYP1A2, CYP3A4, or CYP2D6). This proteolytic clearance is the central reason the drug has a low likelihood of classic pharmacokinetic drug-drug interactions with small-molecule vitamins such as B6. The FDA's 2023 guidance on GLP-1 receptor agonist drug interaction testing reinforces that peptide GLP-1-class agents require few conventional CYP-based interaction studies [3].

Why Supplement Safety Still Deserves Scrutiny

Even without a CYP interaction, any agent that causes significant GI disruption (nausea, vomiting, delayed gastric emptying) can alter the absorption of orally ingested micronutrients. Retatrutide shares this GI profile with the rest of the GLP-1 class. Oral B6 absorption may be modestly reduced on high-nausea days, though no clinical data quantify this specifically for retatrutide.

What Is Vitamin B6 and What Doses Are People Actually Taking?

Vitamin B6 is the collective term for three naturally occurring forms: pyridoxine, pyridoxal, and pyridoxamine, all of which convert to the active coenzyme pyridoxal 5'-phosphate (PLP) in the liver. PLP participates in over 100 enzymatic reactions, most of them related to amino acid metabolism, neurotransmitter synthesis, and glycogen breakdown [4].

Dietary Reference Intakes vs. Supplement Doses

The dietary reference intake for adults aged 19 to 50 is 1.3 mg per day [4]. Most multivitamins supply 2 to 10 mg. B complex formulations often contain 25 to 100 mg. Standalone high-dose pyridoxine tablets marketed for nausea relief or nerve support frequently contain 100 to 500 mg per dose, sometimes more.

The Institute of Medicine set the tolerable upper intake level (UL) at 100 mg per day for adults. Above that threshold, risk of sensory peripheral neuropathy rises progressively, with documented cases appearing consistently above 200 mg per day in the published case literature [5].

Who Is Taking High-Dose B6 While on a GLP-1-Class Drug?

People using retatrutide or semaglutide commonly report nausea, and some independently start taking pyridoxine because it is used (off-label in the US) for nausea of pregnancy. This creates a real-world scenario in which patients may be consuming 50 to 200 mg of B6 daily alongside their injectable weight-loss drug without mentioning it to their prescriber.

Is There a Direct Drug Interaction Between Retatrutide and Vitamin B6?

No known direct pharmacokinetic interaction exists. The concern is pharmacodynamic, not metabolic.

Pharmacokinetic Interaction: Low Risk

Retatrutide does not inhibit or induce any CYP enzyme relevant to B6 metabolism. Pyridoxine conversion to PLP occurs via pyridoxal kinase and pyridoxine 5'-phosphate oxidase, neither of which is affected by GLP-1-class peptides in published data. A 2022 review of GLP-1 receptor agonist drug interactions in Diabetes Care confirmed that CYP-mediated interactions for this drug class are not clinically relevant for micronutrients [6].

Pharmacodynamic Overlap: The Neuropathy Monitoring Problem

This is where clinical attention is warranted. Both high-dose B6 toxicity and, at least theoretically, very high-dose GLP-1 class agents have been associated with peripheral nervous system effects.

Pyridoxine-induced sensory neuronopathy is well characterized. A 2017 systematic review in Drug and Chemical Toxicology (Vrolijk et al.) found that 14 of 23 case reports of B6 neuropathy involved daily intakes below 500 mg, and four involved intakes below 200 mg [5]. Symptoms include progressive numbness and tingling in the hands and feet, unsteady gait, and decreased vibratory sensation.

Retatrutide's neuropathy data are limited. The Phase 2 trial did not report peripheral neuropathy as a significant adverse event [1]. The GLP-1 class as a whole has not been established as a neuropathy risk in randomized controlled trials; the LEADER trial (liraglutide, N=9,340) actually showed a non-significant trend toward reduced peripheral neuropathy in type 2 diabetes [7].

The practical concern: if a patient on retatrutide develops tingling or numbness, and they are also taking 300 mg of pyridoxine daily, the provider cannot easily attribute the symptom to one agent without stopping the B6 first. This confounding problem justifies keeping B6 below the 100 mg UL while on retatrutide.

Gastric Emptying and B6 Absorption

GLP-1 receptor agonists delay gastric emptying. This delays the absorption of orally ingested drugs and supplements, including pyridoxine tablets. Delayed absorption does not reduce total bioavailability for most micronutrients, but the time to peak plasma PLP is likely longer. For therapeutic uses of B6 (for example, premenstrual syndrome symptom management at doses of 50 to 100 mg), this delay may modestly reduce symptom relief on high-nausea days. Switching to a B6 supplement taken with dinner rather than breakfast may partially offset this effect.

Specific Dose Guidance: How Much B6 Is Acceptable with Retatrutide?

The following tiered guidance is derived from the Institute of Medicine tolerable upper intake levels, the B6 neuropathy case literature, and the general pharmacology of GLP-1-class agents. It has not been tested in a dedicated retatrutide-B6 clinical trial.

Tier 1: Dietary and Standard Multivitamin Doses (up to 10 mg/day)

No restriction is needed. This range is far below the UL and does not contribute to neuropathy risk. Patients on retatrutide taking a standard multivitamin containing 2 to 10 mg of B6 can continue without modification.

Tier 2: B Complex and Mid-Range Supplements (10 to 100 mg/day)

Acceptable for most patients. This range remains at or below the 100 mg UL. Patients should inform their prescriber and report any new peripheral sensory symptoms. No specific timing separation is required from the weekly subcutaneous injection of retatrutide, since B6 is oral and the interaction is not time-sensitive.

Tier 3: High-Dose Supplementation (100 to 200 mg/day)

Use with caution and only under prescriber guidance. At this range, individual susceptibility varies. People with pre-existing peripheral neuropathy, those with diabetes, and those with nutritional deficiencies affecting nerve health should have a baseline neurological assessment before starting.

Tier 4: Very High Doses (above 200 mg/day)

Avoid while on retatrutide unless a specific clinical indication exists (for example, B6-responsive homocystinuria or isoniazid co-administration, both of which are managed by specialists). The neuropathy risk is real at this dose range regardless of retatrutide, and the diagnostic confusion it creates is not in the patient's interest.

Why Some People Are Told to Take B6 with Certain Medications (and Whether That Applies Here)

Vitamin B6 at 25 to 50 mg daily is standard prophylaxis against peripheral neuropathy caused by isoniazid (INH), a first-line tuberculosis drug. Isoniazid forms a hydrazone with PLP and depletes functional B6 [8]. People taking both isoniazid and retatrutide (a rare but possible combination) need B6 supplementation at the INH-protective dose, which falls well within the safe range.

Retatrutide itself does not deplete B6. There is no mechanism by which the peptide would form a complex with PLP or inhibit pyridoxal kinase. No supplemental B6 is required for retatrutide's pharmacological activity.

Nutritional Deficiencies on GLP-1 Class Agents: Where B6 Fits In

Significant weight loss, especially when combined with reduced caloric intake, can reduce micronutrient status. The bariatric surgery literature is instructive here. A 2022 review in Obesity Reviews found that patients who lost 15 to 20% of body weight through any method, surgical or pharmacological, were at measurable risk of thiamine, B12, folate, iron, and zinc deficiency [9]. B6 deficiency was less commonly reported but does appear in the literature when dietary variety drops sharply.

Retatrutide's 24.2% weight loss at 48 weeks in Phase 2 [1] approaches sleeve gastrectomy outcomes. That degree of weight loss, combined with reduced appetite and GI side effects limiting food variety, could theoretically reduce dietary B6 intake. Most patients on retatrutide are advised to take a high-quality multivitamin containing the RDI for B6 (1.3 to 2 mg) as nutritional insurance. This is not a mandatory clinical recommendation at present, since retatrutide lacks the long-term post-marketing data that bariatric surgery has accumulated, but it is consistent with prudent practice.

The 2023 American Association of Clinical Endocrinologists (AACE) Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity state: "Micronutrient supplementation should be individualized based on dietary assessment, laboratory monitoring, and clinical findings in patients undergoing significant pharmacological weight reduction" [10].

Monitoring: What to Watch For When Taking Both

Baseline Assessment

Before starting retatrutide, a provider should document any pre-existing peripheral neuropathy symptoms and current supplement use, including all B6-containing products. A baseline serum PLP level is not routinely necessary unless the patient is at high risk (diabetes with neuropathy, malabsorption, chronic alcoholism, or active INH therapy).

On-Treatment Monitoring

Patients should report the following promptly:

• New or worsening numbness, tingling, or burning in the hands or feet
• Unsteady gait or difficulty with balance
• Sensitivity to touch in the extremities

These symptoms overlap with diabetic peripheral neuropathy, which is common in the retatrutide trial population. Any new neurological symptom in a patient taking more than 100 mg of B6 daily should trigger B6 dose reduction first, followed by repeat assessment in four to six weeks.

Laboratory Considerations

Serum PLP can be measured if B6 toxicity is suspected. A level above 200 nmol/L alongside sensory symptoms supports pyridoxine toxicity. This test is available at standard reference laboratories and does not require special preparation.

Special Populations

People with Type 2 Diabetes

Retatrutide Phase 2 included participants across a range of metabolic profiles. Type 2 diabetes independently increases peripheral neuropathy risk. Patients with pre-existing diabetic peripheral neuropathy should keep B6 below 50 mg daily and discuss any planned supplementation with their endocrinologist.

Pregnant Individuals

Retatrutide is not approved and is not recommended in pregnancy. B6 at 10 to 25 mg is used for nausea of pregnancy under obstetric guidance (and is an ingredient in Diclegis/Bonjesta). This combination scenario is clinically irrelevant because retatrutide would be discontinued at confirmed pregnancy.

Older Adults

Adults over 65 have a higher baseline prevalence of peripheral neuropathy from multiple causes. The same 100 mg UL applies, but clinical caution is appropriate at doses above 50 mg given the diminished ability to compensate for B6-induced axonal damage in older nerve tissue.

Practical Takeaways for Patients and Prescribers

Patients already taking a B6-containing multivitamin or a B complex up to 100 mg can continue without stopping retatrutide. The supplement does not reduce retatrutide's efficacy, does not alter its pharmacokinetics, and does not require a different injection timing.

Patients self-treating nausea with high-dose pyridoxine tablets (100 mg or more per dose, sold over the counter) should inform their prescriber. The preferred approach is to manage retatrutide-related nausea through dose titration, eating smaller meals, and avoiding high-fat trigger foods rather than through high-dose B6 supplementation. According to the Phase 2 trial protocol, most GI adverse events resolved with conservative dietary measures and did not require dose reduction [1].

Prescribers reviewing a medication reconciliation that includes B6 above 200 mg daily should reduce the supplement to below 100 mg before initiating retatrutide, document the change, and set a review point at the 12-week titration visit.

The established tolerable upper intake level for vitamin B6 in adults is 100 mg per day [4].